Lupin has been granted non-exclusive license from TB Alliance to manufacture the anti-TB drug pretomanid as part of the three-drug ‘BPaL’ regimen. Lupin intends to commercialize the antituberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.